Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Other Non-Current Liabilities of $6.1 million for Q1 2026, up 172.9% year-over-year from $2.2 million in Q1 2025, and down 16.73% quarter-over-quarter from $7.3 million in Q4 2025.
Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 172.9% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 172.9% YoY), while the FY2025 annual figure was $7.3 million, up 203.51% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $6.1 million, down from $7.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $7.3 million in Q4 2025, with the low at $1.9 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $2.1 million (2025), against an average of $2.6 million.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities fell 18.15% in 2022, then soared 203.51% in 2025.
- Aquestive Therapeutics' Other Non-Current Liabilities stood at $2.0 million in 2022, then decreased by 0.88% to $2.0 million in 2023, then advanced by 18.8% to $2.4 million in 2024, then jumped by 203.51% to $7.3 million in 2025, then decreased by 16.73% to $6.1 million in 2026.
- Business Quant data shows AQST's Other Non-Current Liabilities at $6.1 million in Q1 2026, $7.3 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Aquestive Therapeutics | 560.60 Mn | 560.60 Mn | 9.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.19 Mn |
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 7.27 Mn |
| Sep 30, 2025 | 2.06 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 2.01 Mn |
| Jun 30, 2023 | 2.01 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 2.03 Mn |
| Sep 30, 2022 | 2.16 Mn |
| Jun 30, 2022 | 2.38 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 2.49 Mn |
| Sep 30, 2021 | 1.81 Mn |